sutro biopharma inc - STRO
STRO
Close Chg Chg %
24.87 -1.09 -4.38%
Closed Market
23.78
-1.09 (4.38%)
Volume: 126.59K
Last Updated:
Apr 2, 2026, 4:00 PM EDT
Company Overview: sutro biopharma inc - STRO
STRO Key Data
| Open $24.11 | Day Range 23.65 - 25.39 |
| 52 Week Range 5.23 - 26.35 | Market Cap $393.97M |
| Shares Outstanding 16.57M | Public Float 15.35M |
| Beta 1.31 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$22.65 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 201.99K |
STRO Performance
| 1 Week | -2.66% | ||
| 1 Month | -5.97% | ||
| 3 Months | 116.97% | ||
| 1 Year | 338.66% | ||
| 5 Years | -89.87% |
STRO Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
9
Full Ratings ➔
About sutro biopharma inc - STRO
Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.
STRO At a Glance
Sutro Biopharma, Inc.
111 Oyster Point Boulevard
South San Francisco, California 94080
| Phone | 1-650-881-6500 | Revenue | 102.48M | |
| Industry | Pharmaceuticals: Major | Net Income | -191,086,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 65.182% | |
| Fiscal Year-end | 12 / 2026 | Employees | 137 | |
| View SEC Filings |
STRO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.959 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.968 |
| Enterprise Value to Sales | 1.874 |
| Total Debt to Enterprise Value | 1.224 |
STRO Efficiency
| Revenue/Employee | 748,058.394 |
| Income Per Employee | -1,394,788.321 |
| Receivables Turnover | 25.769 |
| Total Asset Turnover | 0.365 |
STRO Liquidity
| Current Ratio | 2.009 |
| Quick Ratio | 2.009 |
| Cash Ratio | 1.882 |
STRO Profitability
| Gross Margin | 92.854 |
| Operating Margin | -102.408 |
| Pretax Margin | -186.545 |
| Net Margin | -186.454 |
| Return on Assets | -68.119 |
| Return on Equity | N/A |
| Return on Total Capital | -185.957 |
| Return on Invested Capital | -113.722 |
STRO Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 228.897 |
| Total Debt to Total Assets | 135.31 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 221.323 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Sutro Biopharma Inc - STRO
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 67.77M | 153.73M | 62.04M | 102.48M | |
Sales Growth
| +9.52% | +126.84% | -59.64% | +65.18% | |
Cost of Goods Sold (COGS) incl D&A
| 8.29M | 6.82M | 7.22M | 7.32M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 8.29M | 6.82M | 7.22M | 7.32M | |
Depreciation
| - | 6.82M | 7.22M | 7.32M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| -15.19% | -17.76% | +5.90% | +1.47% | |
Gross Income
| 59.48M | 146.91M | 54.83M | 95.16M | |
Gross Income Growth
| +14.16% | +146.98% | -62.68% | +73.57% | |
Gross Profit Margin
| +87.77% | +95.57% | +88.37% | +92.85% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 188.43M | 236.19M | 293.28M | 200.11M | |
Research & Development
| 137.17M | 180.43M | 252.04M | 166.42M | |
Other SG&A
| 51.26M | 55.77M | 41.23M | 33.70M | |
SGA Growth
| +25.09% | +25.35% | +24.17% | -31.77% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | (12.13M) | (9.92M) | 53.41M | |
EBIT after Unusual Expense
| (116.81M) | (79.36M) | (238.45M) | (158.37M) | |
Non Operating Income/Expense
| 3.46M | 4.63M | 50.78M | 5.40M | |
Non-Operating Interest Income
| 3.46M | 14.51M | 18.64M | 9.25M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 3.35M | 13.87M | 37.43M | 38.21M | |
Interest Expense Growth
| +6.66% | +314.52% | +169.84% | +2.09% | |
Gross Interest Expense
| 3.35M | 13.87M | 37.43M | 38.21M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (116.70M) | (88.60M) | (225.10M) | (191.18M) | |
Pretax Income Growth
| -10.58% | +24.08% | -154.06% | +15.07% | |
Pretax Margin
| -172.20% | -57.63% | -362.81% | -186.55% | |
Income Tax
| 2.50M | 18.19M | 2.36M | (93.00K) | |
Income Tax - Current - Domestic
| - | 17.25M | 2.36M | (93.00K) | |
Income Tax - Current - Foreign
| - | - | - | 943.00K | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (119.20M) | (106.79M) | (227.46M) | (191.09M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (119.20M) | (106.79M) | (227.46M) | (191.09M) | |
Net Income Growth
| -12.95% | +10.41% | -112.99% | +15.99% | |
Net Margin Growth
| -175.89% | -69.47% | -366.62% | -186.45% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (119.20M) | (106.79M) | (227.46M) | (191.09M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (119.20M) | (106.79M) | (227.46M) | (191.09M) | |
EPS (Basic)
| -23.4935 | -17.7505 | -29.6061 | -22.4865 | |
EPS (Basic) Growth
| -2.66% | +24.45% | -66.79% | +24.05% | |
Basic Shares Outstanding
| 5.07M | 6.02M | 7.68M | 8.50M | |
EPS (Diluted)
| -23.4935 | -17.7505 | -29.6061 | -22.4865 | |
EPS (Diluted) Growth
| -2.66% | +24.45% | -66.79% | +24.05% | |
Diluted Shares Outstanding
| 5.07M | 6.02M | 7.68M | 8.50M | |
EBITDA
| (120.66M) | (82.46M) | (231.24M) | (97.63M) | |
EBITDA Growth
| -35.95% | +31.65% | -180.41% | +57.78% | |
EBITDA Margin
| -178.03% | -53.64% | -372.70% | -95.26% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 32.00 | |
| Number of Ratings | 9 | Current Quarters Estimate | -2.879 | |
| FY Report Date | 06 / 2026 | Current Year's Estimate | -9.548 | |
| Last Quarter’s Earnings | -2.59 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -22.49 | Next Fiscal Year Estimate | -8.135 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 9 | 9 | 8 | 8 |
| Mean Estimate | -2.88 | -2.80 | -9.55 | -8.14 |
| High Estimates | -1.43 | -1.33 | -5.42 | -3.53 |
| Low Estimate | -4.87 | -5.85 | -15.74 | -13.94 |
| Coefficient of Variance | -40.03 | -47.62 | -32.78 | -45.44 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 7 | 7 | 6 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 1 | 1 | 3 |
| UNDERWEIGHT | 1 | 0 | 1 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Buy | Overweight |
SEC Filings for Sutro Biopharma Inc - STRO
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Sutro Biopharma Inc - STRO
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| May 20, 2025 | Edward C. Albini CFO AND SECRETARY | 167,675 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 20, 2025 | Edward C. Albini CFO AND SECRETARY | 176,800 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 20, 2025 | Edward C. Albini CFO AND SECRETARY | 160,805 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.88 per share | 141,508.40 |
| May 20, 2025 | Edward C. Albini CFO AND SECRETARY | 27,312 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 20, 2025 | Edward C. Albini CFO AND SECRETARY | 4,594 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 20, 2025 | Edward C. Albini CFO AND SECRETARY | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 20, 2025 | Edward C. Albini CFO AND SECRETARY | 156,519 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 9, 2025 | Venkatesh Srinivasan CHIEF TECH OP OFFICER | 94,250 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 9, 2025 | Venkatesh Srinivasan CHIEF TECH OP OFFICER | 101,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 9, 2025 | Jane Chung Chief Executive Officer; Director | 310,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 9, 2025 | Jane Chung Chief Executive Officer; Director | 620,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 9, 2025 | David Pauling Chief Admin. Ofcr. & GC | 94,250 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 9, 2025 | David Pauling Chief Admin. Ofcr. & GC | 101,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 9, 2025 | Hans-Peter Gerber CHIEF SCIENTIFIC OFFICER | 113,750 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 9, 2025 | Hans-Peter Gerber CHIEF SCIENTIFIC OFFICER | 122,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 9, 2025 | Barbara Leyman Chief Business Dev. Officer | 84,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 9, 2025 | Barbara Leyman Chief Business Dev. Officer | 91,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |